BrainXell Therapeutics announced recently preclinical data demonstrating the efficacy of its neuronal therapy called BXT-110 as a potential disease-modifying treatment for Parkinson’s disease.

BrainXell Therapeutics is using induced pluripotent stem cells (iPSCs) to restore dopaminergic neurons as a regenerative approach for Parkinson’s disease.

“Importantly, these results highlight our capability to advance development of iPSC-derived therapies that can be transformative for patients living with neurodegenerative diseases,” CEO Katherine Vega Stultz said in a statement. “We are excited to be advancing BXT-110 as a potential treatment of Parkinson’s disease.”

According to a release, the results of in vivo studies establish BXT-110 as a highly reproducible personalized cell-therapy candidate. 

BrainXell presented the data last month at the Cell Symposia in Los Angeles and the Society for Neuroscience Annual Meeting in San Diego.